OBJECTIVE: Coumarin anticoagulants are prone to potentially life-threatening drug-drug interactions due to a combination of unfavorable properties. However, real life data on the actual occurrence are scarce. The aim of this study was to quantify and qualify potential drug interactions with coumarin anticoagulants in daily practice. METHODS: A cohort study including all users of phenprocoumon or acenocoumarol during the period 1991-2003 in the PHARMO Record Linkage System. All 24 individual drugs and 11 drug groups interacting with coumarins according to central database used in the Dutch pharmacies were considered. MAIN OUTCOME MEASURE: Frequency and type of potential drug interactions during anticoagulant therapy with coumarins. RESULTS: 48,627 out of 76,455 mainly acenocoumarol-users (64%) were dispensed at least one potentially interacting drug (PID) during anticoagulant therapy. About 35% of these cases were dispensed a (very) strongly interacting drug, whereas 3% were dispensed a contraindicated drug. Antibacterial drugs and NSAIDs (39% and 37% of all users, respectively) were the most frequently dispensed PIDs. CONCLUSION: Potential drug interactions with coumarins frequently occur in daily practice, confronting two-thirds of patients with an increased risk of bleeding. To a large part, this is attributable to commonly prescribed medication like antibacterial drugs and NSAIDs. This situation substantiates the need for proper monitoring or new anticoagulants with less drug-drug interactions.
OBJECTIVE:Coumarin anticoagulants are prone to potentially life-threatening drug-drug interactions due to a combination of unfavorable properties. However, real life data on the actual occurrence are scarce. The aim of this study was to quantify and qualify potential drug interactions with coumarin anticoagulants in daily practice. METHODS: A cohort study including all users of phenprocoumon or acenocoumarol during the period 1991-2003 in the PHARMO Record Linkage System. All 24 individual drugs and 11 drug groups interacting with coumarins according to central database used in the Dutch pharmacies were considered. MAIN OUTCOME MEASURE: Frequency and type of potential drug interactions during anticoagulant therapy with coumarins. RESULTS: 48,627 out of 76,455 mainly acenocoumarol-users (64%) were dispensed at least one potentially interacting drug (PID) during anticoagulant therapy. About 35% of these cases were dispensed a (very) strongly interacting drug, whereas 3% were dispensed a contraindicated drug. Antibacterial drugs and NSAIDs (39% and 37% of all users, respectively) were the most frequently dispensed PIDs. CONCLUSION: Potential drug interactions with coumarins frequently occur in daily practice, confronting two-thirds of patients with an increased risk of bleeding. To a large part, this is attributable to commonly prescribed medication like antibacterial drugs and NSAIDs. This situation substantiates the need for proper monitoring or new anticoagulants with less drug-drug interactions.
Authors: Patricia A Howard; Edward F Ellerbeck; Kimberly K Engelman; Kelly L Patterson Journal: Pharmacoepidemiol Drug Saf Date: 2002 Oct-Nov Impact factor: 2.890
Authors: Loes E Visser; Fernie J A Penning-van Bees; A A Harrie Kasbergen; Peter A G M De Smet; Arnold G Vulto; Albert Hofman; Bruno H Ch Stricker Journal: Thromb Haemost Date: 2002-11 Impact factor: 5.249
Authors: G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi Journal: Lancet Date: 1996-08-17 Impact factor: 79.321
Authors: Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells Journal: Arch Intern Med Date: 2005-05-23
Authors: L Gschwind; V Rollason; C Lovis; F Boehlen; P Bonnabry; P Dayer; J A Desmeules Journal: Eur J Clin Pharmacol Date: 2012-08-19 Impact factor: 2.953
Authors: Camilo Molino Guidoni; Helen Palmira Miranda Camargo; Paulo Roque Obreli-Neto; Edmarlon Girotto; Leonardo Regis Leira Pereira Journal: Int J Clin Pharm Date: 2016-06-30
Authors: Hanneke W Drewes; Mattijs S Lambooij; Caroline A Baan; Bert R Meijboom; Wilco C Graafmans; Gert P Westert Journal: BMC Health Serv Res Date: 2011-01-27 Impact factor: 2.655
Authors: Hanneke W Drewes; Mattijs S Lambooij; Caroline A Baan; Bert R Meijboom; Wilco C Graafmans; Gert P Westert Journal: BMC Cardiovasc Disord Date: 2011-12-22 Impact factor: 2.298